Invesco NASDAQ Biotechnology ETF

IBBQ

Market cap $66.8M

Investors are questioning the staying power of medical technology (medtech) stocks, which have fallen from grace since the COVID-19 pandemic. The starting point is to distinguish between medtech and other healthcare industries.

The healthcare sector has experienced one of its most significant de-ratings in 35 years, with valuations now at a 30% discount to the broader market. Healthcare trades at historical valuation discounts across multiple metrics.

Outlook for pharma sector as Trump pushes for regulatory changes. The impact of tariffs on drugmakers.

The Fed lifted market confidence amid economic uncertainty, leading to a rally in the U.S. stock market.

Investors cooled to the healthcare sector in 2024, which dramatically trailed global and US equity markets for the year. any investors are now asking: how will the policy changes under a new US administration affect healthcare companies?

IBBQ is a relatively new U.S. biotech ETF that competes with established peers like IBB and XBI. IBBQ has outperformed both since its June 2021 launch date. However, there are specific risks investors should consider first. In addition to the volatile nature of the biotech industry, I'll review IBBQ's liquidity, concentration, and quality features in detail. IBBQ also has a high liquidation risk. With only $38 million in assets under management and a 0.19% expense ratio, IBBQ likely isn't a profitable product for Invesco.

Following a multiyear run of disappointment, biotech stocks and related ETFs are showing signs of life. For the past 90 days ending February 29, the widely observed Nasdaq Biotechnology Index was higher by almost 17%.

The Nasdaq Composite and the S&P 500 hit new all-time high Friday. However, there are chances of further rally.

The biotech space staged a strong comeback at the start of 2024, driven by multi-billion dollar deals, upbeat clinical results and cutting-edge medical advances like CRISPR gene-editing hitting prime-time.

Wall Street witnessed an upbeat December due to moderation in inflationary pressures, the likelihood of Fed rate cuts in 2024 and decent corporate earnings.